

Programmable T Cell Therapies: From Precision Genome Editing to In Vivo Programming



Dr. Thomas Fox
Harvard Medical School and
University College London

- Monday, 13th of April 2026, 2:00 PM (Ljubljana/Berlin time)
- Teams webinar [Link](#)

Dr. Thomas Fox is a clinician-scientist and Wellcome Trust Early Career Research Fellow working between the Dana-Farber Cancer Institute and Boston Children's Hospital at Harvard Medical School and the UCL Institute of Immunity and Transplantation in London. His research focuses on developing next-generation genome engineering strategies to create safer and more effective immune cell therapies for cancer and inborn errors of immunity. His work combines CRISPR-based editing technologies with targeted delivery platforms such as lipid nanoparticles and virus-like particles to enable both ex vivo engineering and direct in vivo programming of T cells. In this talk, he will discuss emerging strategies for building programmable T-cell therapies, ranging from precision genome editing approaches to technologies that enable therapeutic T cells to be generated directly in patients, with applications in cancer and immune dysregulation.